Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crohn's Drug Gives MediTech Big Break (China)

This article was originally published in PharmAsia News

Executive Summary

Hutchison China MediTech's experimental drug HMPL-004 for treating Crohn's disease has performed well in phase-II clinical trials and looks promising for eventual approval. Current data shows HMPL-004 at least as effective as current available therapies. The drug is based on a compound used in traditional Chinese, and it is targeting treatment of ulcerative colitis and Crohn's disease. Both diseases are autoimmune diseases of the upper and lower intestines, and modern pharmaceutical medicine can help about 60 percent of patients. The company is owned by Hong Kong-based Hutchison. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066412

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel